News
-
ADHD care boost
Friday | Oct 18 2024GREATER support is needed for Tasmanian GPs to assess and treat patients with ADHD, said Royal Australian College of GP's member, Dr Tim Jones.
-
CMA phishing hit
Friday | Oct 18 2024COMPLEMENTARY Medicines Australia is advising members of a cyber security breach that may have seen some personal details accessed.
-
APP ending early
Friday | Oct 18 2024PHARMACY Guild of Australia's Queensland branch have said they are acting on member feedback and closing the 2025 APP conference on Sat over the traditional Sun.
-
Consider savings
Friday | Oct 18 2024WHETHER it's catalogue pre-order rebates, dispensary assistance subscriptions or bonus stock, aligning with Chemsave delivers bottom line benefits - learn more about a special offer on page three.
-
Ramsay’s finest
Friday | Oct 18 2024RAMSAY Pharmacy is today celebrating the success of its recent group-wide conference, which brought together superstars from across the business to chart growth into 2025 - see more on page four.
-
Reasons to smile
Friday | Oct 18 2024GLUCOJEL is offering your customers the chance to win $10,000 with purchases across the Glocujel jellybean range, so make sure your shelves are fully stocked - more on the giveaway on page five.
-
AMA calls for pay
Friday | Oct 18 2024MEDICAL students must be included in the Federal Government's Commonwealth Prac Payments scheme to boost access to care, especially in rural and remote areas.
-
Dispensary Corner 18 Oct 24
Friday | Oct 18 2024MOTHERS and daughters often solve problems together, but restoring historic Spanish church frescoes using bacteria is rarely on the list of those issues commonly conquered.
-
TWC against CW merger
Thursday | Oct 17 2024TERRYWHITE Chemmart CEO John Cullity says the planned merger between Chemist Warehouse and Sigma Healthcare would reduce choice in the market and potentially impact smaller businesses negatively.
-
TGA rejects lecanemab
Thursday | Oct 17 2024THE Therapeutic Goods Administration (TGA) has decided that it will not register Lecanemab (LEQEMBI), a medication for people living with mild cognitive impairment and the early stages of Alzheimer's disease, as "the demonstrated efficacy did not outweigh the safety risks".
